Sanj K. Patel
President & Chief Executive Officer and Director
Sanj K. Patel was appointed President and Chief Executive Officer and elected as a director of Synageva in June 2008. He created the vision and strategy for Synageva, launched its focus on rare diseases, and designed and initiated its lead program for LAL Deficiency in July 2008. He took the company public on the NASDAQ Global Market in November 2011 and since 2009, has raised over $800 million in capital. Sanj has more than 20 years of experience in the pharmaceutical and biotech industries and has a combination of scientific, clinical and commercial skills. He joined Synageva from Genzyme Corporation (1999-2008) where most recently he was the head of U.S. Sales, Marketing and Commercial Operations for Genzyme Therapeutics’ Lysosomal Storage Disorder franchise and led the U.S. launch of Myozyme in addition to sales and marketing responsibility for Cerezyme, Fabrazyme and Aldurazyme. Previously, Sanj held several cross-functional senior leadership roles at Genzyme, including Vice President, Clinical Research and Head of the Global Clinical Research Operations Council. He was responsible for clinical operations and development for all cross-business Genzyme products and was instrumental in the path to commercialization for several treatments. Notably, Sanj led the Fabrazyme clinical operations team and development program to FDA approval in April 2003. Prior to Genzyme, Sanj held roles in clinical research and commercial development with increasing levels of responsibility at Burroughs Wellcome, Hoechst Marrion Roussel and Fujisawa Pharmaceuticals. Sanj obtained his BSc with Honors in Pure and Applied Biology (Biotechnology) from the University of the South Bank, London. He completed his post-graduate management and business degree, and doctorate level research program at Ealing College, London, and the Wellcome Foundation, respectively. Sanj is a member of the Board of Directors for the Sarcoma Foundation of America and Intercept Pharmaceuticals, Inc.
Back To Top
Senior Vice President, Chief Financial Officer
Carsten Boess joined Synageva in May 2011 as Senior Vice President and Chief Financial Officer. He is responsible for leading Synageva’s financial and strategic operations. Carsten has more than 20 years of financial operations and management experience in the life sciences industry with diversified experience across a broad field of areas both in the U.S. and internationally. Prior to joining Synageva, Carsten served in the roles of Chief Financial Officer and Vice President, International of Insulet Corporation, respectively (June 2006-2011) and has also served in the following capacities: Chief Financial Officer of Alexion Pharmaceuticals, Inc., Executive Vice President of Finance for Serono, Inc. and Vice President Finance, International Operations, Novo Nordisk. Carsten has significant international experience having served as head of finance of companies in the U.S., Denmark, China, Switzerland, and France. He also headed the expansion of Insulet’s business internationally in the role of Vice President, International. Carsten earned a Bachelor’s and Master’s degree in economics and finance from the University of Odense, Denmark.
Back To Top
Chief Operating Officer
Robert Bazemore joined Synageva in September 2014 as Chief Operating Officer with responsibility for the company’s global commercial, market access and medical affairs operations. Robert has over 22 years of biopharmaceutical experience, with the last 12 years at Johnson & Johnson in various roles including Vice President, Ethicon New Growth Platforms and President of Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson. In his role as President of Janssen Biotech, Robert was responsible for building Janssen’s U.S. Immunology and Oncology businesses, which generated more than $7 billion in annual revenues. Mr. Bazemore began his career at Johnson & Johnson in 2002 and held numerous senior commercial positions having led the worldwide Immunology portfolio strategy and the launches of multiple new products and indications.
As President of Janssen Biotech, Robert was responsible for the growth and diversification of the U.S. Immunology and Oncology businesses, including major brands such as Remicade®(infliximab) and Procrit®(epoetin alfa), and the launches of Simponi®(golimumab), Stelara® (ustekinumab), Zytiga®(abiraterone) and Imbruvica®(ibrutinib), among others. In addition to his achievements with these products, Robert also played an instrumental role in business development, including Johnson & Johnson’s acquisition of Cougar Biotechnology, Inc. in 2009, and Johnson & Johnson’s partnership with Pharmacyclics, Inc., in 2011. During his career at Johnson & Johnson, Robert also served as Vice President, Marketing and Sales of Centocor Ortho Biotech, Inc., and Worldwide Vice President, Global Strategic Marketing. Prior to joining Johnson & Johnson, Robert worked at Merck & Co., Inc. for eleven years in roles of increasing responsibility in Medical Affairs, Sales and Marketing, including Worldwide Marketing, Respiratory Franchise Business Group, and was a member of the marketing team that launched Singulair® (montelukast) in the U.S. Robert obtained a Bachelor of Science, Biochemistry from the University of Georgia.
Back To Top
Anthony Quinn, MBChB (MD), PhD, FRCP
Executive Vice President, Chief Medical Officer, and
Head of Research & Development
Anthony G. Quinn, MBChB (MD), PhD, FRCP joined Synageva in August 2009. Prior to joining Synageva, he was Vice President and Global Head of Clinical Research & Exploratory Development for Inflammation at Roche. While at Roche, Anthony managed programs in rheumatology and respiratory indications in exploratory development, and biomarker and translational medicine activities in the late clinical and registration phase for MabThera™/Rituxan™, Actemra™ and Ocrelizumab. Anthony joined Roche in 2005 to build the translational medicine and exploratory development capabilities at the site across a broad range of therapeutic areas including CNS, virology and inflammation. Prior to joining Roche, he was Director of Experimental Medicine at AstraZeneca, Charnwood in the UK, and before that he was Professor of Dermatology at Barts & The London School of Medicine, London, England. He has authored or co-authored more than 50 peer-reviewed journal articles, book chapters, reviews and editorials, predominantly on Hedgehog signaling and the molecular biology of non-melanoma skin cancer. He received his Bachelor of Medical Science with First class honors and his MBChB (MD) with commendation from the University of Dundee, UK. Anthony trained in internal medicine, dermatology and molecular biology at the University of Newcastle upon Tyne and was also awarded his PhD there. He completed a postdoctoral fellowship at University of California, San Francisco, and is a fellow of the Royal College of Physicians London.
Back To Top
Gregory Grabowski, MD
Chief Scientific Officer
Gregory Grabowski, MD, joined Synageva in November 2013 as Chief Scientific Officer. Previously, Dr. Grabowski served as the Director of the Division of Human Genetics at Cincinnati Children’s Hospital Research Foundation and as Professor of Microbiology, Biochemistry, and Pediatrics at the University Of Cincinnati College Of Medicine, Cincinnati, Ohio. Dr. Grabowski is a leading authority in genetic and lysosomal storage diseases, including Gaucher and Fabry disease, and was an early pioneer in understanding LAL Deficiency. In his role as Chief Scientific Officer, Dr. Grabowski will evaluate, design, and implement strategies to advance Synageva's pipeline programs. His experience will be helpful in further developing key relationships across the entire rare disease landscape, including medical providers, researchers and patient advocacy organizations. Dr. Grabowski has authored more than 240 scientific publications and is a regular reviewer of 10 different medical journals. His research interests include lysosomal storage diseases and the study of enzyme therapy in genetic diseases. His research, particularly in lysosomal storage diseases, has been funded by the National Institutes of Health for the past 25 years. Dr. Grabowski received his BA from the University of Minnesota and his MD from the University of Minnesota Medical School.
Back To Top
Stephen Mahoney, JD, MBA
Senior Vice President, U.S. and European Business Operations
Steve Mahoney joined Synageva in September of 2012. He is responsible for Synageva’s business operations in the United States and in Europe. Previously, Steve served as Synageva’s General Counsel and Vice President of Corporate Development. Steve came to Synageva after 9 years with Genzyme Corporation. His background includes global support of operations and commercial execution, particularly the global efforts of several therapeutic business units within Genzyme, including as Genzyme’s Regional Legal Director for the Japan/Asia-Pacific region based in Singapore. Prior to Genzyme, Steve was a corporate attorney with Mintz Levin in Boston. He holds a joint JD/MBA degree from Boston College and BA from Colorado College.
Back To Top
Senior Vice President, Global Technical Operations and Quality
Glen Williams joined Synageva in September of 2012 as Senior Vice President of Global Technical Operations with responsibility for our global supply chain, including oversight of the Manufacturing and Quality organizations. He brings over 25 years of industry experience, most recently as Chief Operating Officer for Caliber Biotherapeutics. Glen was previously Senior Vice President of Technical Operations for Biolex Therapeutics focusing on the development of human therapeutic proteins through the use of a high level plant system for therapeutic protein production. Prior to joining Biolex, Mr. Williams was the Vice President of Manufacturing and General Manager for Biogen Idec's Research Triangle Park facilities where he was responsible for site-wide manufacturing operations for new and marketed recombinant therapeutic proteins. In his ten years with Biogen Idec, Mr. Williams built and successfully licensed two biopharmaceutical production facilities with multiple regulatory authority approvals in addition to launching three commercial biopharmaceutical products, two of which exceeded one billion dollars in annual revenues. In addition to managing major GMP biomanufacturing and supply chain operations, he has an extensive background in the design, construction, startup and licensing of new biopharmaceutical production facilities. Mr. Williams received his MBA from Central Michigan University and his BS in Mechanical Engineering from The Ohio State University.
Back To Top
Mark Hayes, PhD
Senior Vice President, Regulatory Affairs
Dr. Hayes joined Synageva in August 2011, and has 20+ years of experience in research and development of protein therapeutics. Prior to Synageva, he was Group Vice President of Regulatory Affairs at Genzyme Corporation, where over 11 years he led the regulatory function for the Oncology and Biosurgery business units as well as the CMC regulatory organization for all of Genzyme’s therapeutic products. While at Genzyme, he played a critical role in securing global regulatory approvals for a number of innovative products for rare diseases. Prior to moving to industry, Dr. Hayes served at FDA for over 9 years at the Center for Biologics Evaluation and Research, Division of Therapeutic Proteins, where he conducted independent research in cytokine biology and managed the review of numerous recombinant proteins under development for a wide variety of indications. Dr. Hayes received a BS from Davidson College and holds a PhD in Immunology and Experimental Pathology from the University of Florida. He completed post-doctoral fellowship at the National Cancer Institute in Bethesda, MD before joining FDA.
Back To Top
Senior Vice President, Global Commercial Operations
Mike Glynn joined Synageva in September of 2012 as Senior Vice President of Global Commercial Operations. He brings more than 30 years of experience in commercial operations, most recently as Chief Commercial Officer at Pacific Biosciences. Mike’s prior experience includes serving as Regional President, Japan - Asia Pacific and Senior Vice President at Genzyme Corporation. In this role, Mike was responsible for leading and managing Genzyme's businesses, including the Lysosomal Storage Disease products, in Japan and Asia Pacific from the company’s regional headquarters in Singapore. Prior to joining Genzyme in January 2007, he was with Boston Scientific for seven years, most recently as President of its Endovations division in the United States, and prior to that as Vice President and General Manager, Asia, Middle East, and Turkey. Mike holds an MBA from Macquarie University in Sydney and a BS from the National University of Ireland.
Back To Top
Sandra Rojas-Caro, MD
Group Vice President, Clinical Research and Development
Dr. Rojas joined Synageva in January 2013 and will be focused initially on the clinical development of SBC-103, an enzyme replacement for Mucopolysaccharidosis IIIB. She brings more than 10 years of protein therapeutic and small molecule drug development, most recently as Translational Medicine Leader at Roche where she led exploratory development activities for a number of development programs. Prior to Roche, Sandra held roles in clinical and translational research with increasing levels of responsibility at Array BioPharma and Pfizer where she was responsible for the design and implementation of early phase clinical studies across a broad range of indications including RA, IBD, asthma, pain and diabetes. She received her Bachelor of Medical Science and her MD from the Pontifical Catholic University of Chile and trained in molecular biology at the University of Lausanne, Switzerland.
Back to Top
Group Vice President, Global Clinical Operations
Jill Buck joined Synageva in June of 2013 after seven years with Ziopharm, Inc. where she had primary responsibility for the global clinical programs for palifosfamide. She previously had responsibility for their multiple early stage small molecule programs. Jill started her career in clinical operations working at the Thrombolysis in Myocardial Infarction (TIMI) Study Group, an Academic Research Organization of Brigham and Women’s Hospital and Harvard Medical School, and has over 15 years of experience in Phase I-IV clinical development, with a focus on rare diseases. During her career, Jill has held positions of increasing levels of responsibilities in clinical program management, data management and operations at Control Delivery Systems, Averion International, Millennium Pharmaceuticals and Ziopharm. Jill holds a BA from Boston College.
Back to Top
Mark Goldberg, MD
Executive Vice President, Global Medical and Regulatory Strategy
Mark Goldberg, MD joined Synageva in September 2011 and is responsible for Global Medical and Regulatory Strategy. Dr. Goldberg joins Synageva from Genzyme Corporation, where he most recently served as Senior Vice President, Clinical Development and Global Therapeutic Group Head, Oncology and Personalized Genetic Health. While at Genzyme, he played a central role in the development and approval of some of the benchmark therapies for rare diseases, including Fabrazyme®, Aldurazyme®, Myozyme® and Lumizyme®. Prior to working at Genzyme, he was a full time staff physician at Brigham and Women’s Hospital and Dana Farber Cancer Institute, where he still holds appointments. He is also a Clinical Associate Professor of Medicine at Harvard Medical School. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. Reporting directly to Sanj Patel and working very closely with Dr. Anthony Quinn, Synageva’s Chief Medical Officer, Dr. Goldberg will be responsible for product development, medical and regulatory affairs and ensuring the successful progress and advancement of pipeline programs. Dr. Goldberg received his AB (magna cum laude) from Harvard College and his MD (cum laude) from Harvard Medical School.
Back To Top
Thomas Beetham, JD, MBA
Vice President, General Counsel and Corporate Development
Tom Beetham joined Synageva in October 2013 as Vice President, General Counsel & Corporate Development. Tom has over 15 years of transactional and legal experience in the life sciences industry. He was most recently with New England Biolabs, Inc. where he was responsible for all legal matters and a member of Biolabs' Global Business Development team. Prior to Biolabs, Tom was with Genzyme Corporation where he was the senior corporate attorney responsible for Genzyme's Oncology and Multiple Sclerosis business units. Before Genzyme, Tom was a corporate and securities attorney with the law firm of Palmer & Dodge, LLP in Boston. He received his JD and MBA degrees from Boston College, and a BA from the University of Rochester.
Back to Top